Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.